Market research
AP8N.F Aptevo Therapeutics Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 61K
- P/E ratio
- Not available
- Analyst target
- 59.5
- Dividend yield
- Not available
- Beta
- 4.91
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US03835L2079
- Market cap
- 61K
- P/E ratio
- Not available
- Analyst target
- 59.5
- Dividend yield
- Not available
- Beta
- 4.91
About
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AP8N.F discussion.
5 years, 5 months ago
Aptevo Therapeutics Inc is currently in a long term downtrend where the price is trading 28.0% below its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.8.
Aptevo Therapeutics Inc's total revenue sank by 73.7% to $2M since the same quarter in the previous year.
Its net income has increased by 13.7% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 21.8% to $-6M since the same quarter in the previous year.
Based on the above factors, Aptevo Therapeutics Inc gets an overall score of 2/5.